301 related articles for article (PubMed ID: 32163830)
1. TERT promoter mutations and telomeres during tumorigenesis.
Lorbeer FK; Hockemeyer D
Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the promoter of the telomerase gene
Chiba K; Lorbeer FK; Shain AH; McSwiggen DT; Schruf E; Oh A; Ryu J; Darzacq X; Bastian BC; Hockemeyer D
Science; 2017 Sep; 357(6358):1416-1420. PubMed ID: 28818973
[No Abstract] [Full Text] [Related]
3. DNA methylation of the TERT promoter and its impact on human cancer.
Lee DD; Komosa M; Nunes NM; Tabori U
Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations in telomere biology.
Heidenreich B; Kumar R
Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
[TBL] [Abstract][Full Text] [Related]
5. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U
J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567
[TBL] [Abstract][Full Text] [Related]
6. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo.
Miki S; Koga T; Mckinney AM; Parisian AD; Tadokoro T; Vadla R; Marsala M; Hevner RF; Costello JF; Furnari F
Neuro Oncol; 2022 Dec; 24(12):2063-2075. PubMed ID: 35325218
[TBL] [Abstract][Full Text] [Related]
8. TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma.
Chun-On P; Hinchie AM; Beale HC; Gil Silva AA; Rush E; Sander C; Connelly CJ; Seynnaeve BKN; Kirkwood JM; Vaske OM; Greider CW; Alder JK
Science; 2022 Nov; 378(6620):664-668. PubMed ID: 36356143
[TBL] [Abstract][Full Text] [Related]
9. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
12. Classifying Melanoma by TERT Promoter Mutational Status.
Shaughnessy M; Njauw CN; Artomov M; Tsao H
J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation Profiling of hTERT Gene Alongside with the Telomere Performance in Gastric Adenocarcinoma.
Vahidi S; Norollahi SE; Agah S; Samadani AA
J Gastrointest Cancer; 2020 Sep; 51(3):788-799. PubMed ID: 32617831
[TBL] [Abstract][Full Text] [Related]
14. Understanding TERT Promoter Mutations: A Common Path to Immortality.
Bell RJ; Rube HT; Xavier-Magalhães A; Costa BM; Mancini A; Song JS; Costello JF
Mol Cancer Res; 2016 Apr; 14(4):315-23. PubMed ID: 26941407
[TBL] [Abstract][Full Text] [Related]
15. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
16. Systematic analysis of telomere length and somatic alterations in 31 cancer types.
Barthel FP; Wei W; Tang M; Martinez-Ledesma E; Hu X; Amin SB; Akdemir KC; Seth S; Song X; Wang Q; Lichtenberg T; Hu J; Zhang J; Zheng S; Verhaak RG
Nat Genet; 2017 Mar; 49(3):349-357. PubMed ID: 28135248
[TBL] [Abstract][Full Text] [Related]
17. Occurrence, functionality and abundance of the TERT promoter mutations.
Rachakonda S; Hoheisel JD; Kumar R
Int J Cancer; 2021 Dec; 149(11):1852-1862. PubMed ID: 34313327
[TBL] [Abstract][Full Text] [Related]
18. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis.
Kunieda J; Yamashita K; Togashi Y; Baba S; Sakata S; Inamura K; Ae K; Matsumoto S; Machinami R; Kitagawa M; Takeuchi K
Cancer Sci; 2022 Mar; 113(3):1078-1089. PubMed ID: 34971481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]